{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:37:21Z","timestamp":1792255041372,"version":"4.4.0"},"reference-count":87,"publisher":"Cambridge University Press (CUP)","issue":"10","license":[{"start":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T00:00:00Z","timestamp":1493251200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>In 2014, the Food and Drug Administration approved a new human papillomavirus 9-valent vaccine (9vHPV), targeting nine HPV types: HPV types 6, 11, 16, and 18, which are also targeted by the quadrivalent HPV vaccine (qHPV), plus five additional high cancer risk HPV types (HPV types 31, 33, 45, 52, and 58). The aim of the current study was to systematically retrieve, qualitatively and quantitatively pool, as well as critically appraise all available evidence on 9vHPV from randomized controlled trials (RCTs). We conducted a systematic review of the literature on 9vHPV efficacy, immunogenicity and safety, as well as a systematic search of registered, completed, and ongoing RCTs. We retrieved and screened 227 records for eligibility. A total of 10 publications reported on RCTs\u2019 results on 9vHPV and were included in the review. Sixteen RCTs on 9vHPV have been registered on RCT registries. There is evidence that 9vHPV generated a response to HPV types 6, 11, 16 and 18 that was non-inferior to qHPV. Vaccine efficacy against five additional HPV type-related diseases was directly assessed on females aged 16\u201326 years (risk reduction against high-grade cervical, vulvar or vaginal disease = 96\u00b77%, 95% CI 80\u00b79%\u201399\u00b78%). Bridging efficacy was demonstrated for males and females aged 9\u201315 years and males aged 16\u201326 years (the lower bound of the 95% CIs of both the geometric mean titer ratio and difference in seroconversion rates meeting the criteria for non-inferiority for all HPV types). Overall, 9vHPV has been proved to be safe and well tolerated. Other RCTs addressed: 9vHPV co-administration with other vaccines, 9vHPV administration in subjects that previously received qHPV and 9vHPV efficacy in regimens containing fewer than three doses. The inclusion of additional HPV types in 9vHPV offers great potential to expand protection against HPV infection. However, the impact of 9vHPV on reducing the global burden of HPV-related disease will greatly depend on vaccine uptake, coverage, availability, and affordability.<\/jats:p>","DOI":"10.1017\/s0950268817000747","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T04:22:55Z","timestamp":1493266975000},"page":"1962-1982","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":61,"title":["Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence"],"prefix":"10.1017","volume":"145","author":[{"given":"C.","family":"SIGNORELLI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5657-9774","authenticated-orcid":false,"given":"A.","family":"ODONE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"CIORBA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"CELLA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"AUDISIO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"LOMBARDI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"MARIANI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. S.","family":"MENNINI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"PECORELLI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"REZZA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.V.","family":"ZUCCOTTI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"PERACINO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2017,4,27]]},"reference":[{"key":"S0950268817000747_ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28541"},{"key":"S0950268817000747_ref63","volume-title":"Human Papillomavirus (HPV)-Associated Cancers","year":"2015"},{"key":"S0950268817000747_ref78","unstructured":"Department of Health and Human Services. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP). Summary Report February 24, 2016, Atlanta, Georgia (http:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/min-archive\/min-2016-02.pdf)."},{"key":"S0950268817000747_ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.04.068"},{"key":"S0950268817000747_ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.06.001"},{"key":"S0950268817000747_ref67","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0775"},{"key":"S0950268817000747_ref21","unstructured":"European Medicines Agency (http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003852\/human_med_001863.jsp&mid=WC0b01ac058001d124)."},{"key":"S0950268817000747_ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.1202"},{"key":"S0950268817000747_ref65","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0410"},{"key":"S0950268817000747_ref64","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0649"},{"key":"S0950268817000747_ref58","unstructured":"Society of Obstetricians and Gynaecologists of Canada [website]. Gardasil 9 HPV vaccine now available in Canada. Ottawa, ON: Society of Obstetricians and Gynaecologists of Canada, 2015 (http:\/\/sogc.org\/news_items\/gardasil-9-hpv-vaccine-now-available-in-canada-2\/)."},{"key":"S0950268817000747_ref51","unstructured":"NCT01984697. A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose Regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Administered in Preadolescents and Adolescents (9 to 14 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds) (V503-010). In: ClinicalTrials.gov. Merck Sharp & Dohme Corp., 2013 (https:\/\/clinicaltrials.gov\/show\/NCT01984697)."},{"key":"S0950268817000747_ref50","unstructured":"NCT00943722. A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds) (V503-002). In: ClinicalTrials.gov. Merck Sharp & Dohme Corp., 2009 (https:\/\/clinicaltrials.gov\/show\/NCT00943722)."},{"key":"S0950268817000747_ref49","unstructured":"EUCTR2015-004524-65-DK. Efficacy of nonavalent vaccine against human papilloma virus (HPV) in HIV infected sexually active men who have sex with men (MSM) \u2013 HPV-VAX (Inf.Q002). Odense University \u2013 Department of Infectious Diseases. In: EUCTR, 2015 (https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-004524-65)."},{"key":"S0950268817000747_ref47","unstructured":"NCT02567955. Immunogenicity and Safety of Gardasil-9 and Cervarix When Administered to 9\u201310-year-old Subjects According to 0\u20136 Month Schedule (HPV 2355). In: ClinicalTrials.gov. Laval University, 2015 (https:\/\/clinicaltrials.gov\/show\/NCT02567955)."},{"key":"S0950268817000747_ref44","unstructured":"European Medicines Agency. Note for guidance on the clinical evaluation of vaccines (http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003875.pdf). Accessed 14 January 2017."},{"key":"S0950268817000747_ref43","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000773"},{"key":"S0950268817000747_ref56","doi-asserted-by":"publisher","DOI":"10.1080\/10543400600719251"},{"key":"S0950268817000747_ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.06.056"},{"key":"S0950268817000747_ref74","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs395"},{"key":"S0950268817000747_ref39","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1009819"},{"key":"S0950268817000747_ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.08.059"},{"key":"S0950268817000747_ref42","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-3745"},{"key":"S0950268817000747_ref86","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.03.020"},{"key":"S0950268817000747_ref31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"S0950268817000747_ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2014.09.003"},{"key":"S0950268817000747_ref76","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29532"},{"key":"S0950268817000747_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.03.1258"},{"key":"S0950268817000747_ref73","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-1779-1"},{"key":"S0950268817000747_ref20","unstructured":"U.S. Food and Drug Administration (http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm426485.htm)."},{"key":"S0950268817000747_ref69","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv403"},{"key":"S0950268817000747_ref33","doi-asserted-by":"publisher","DOI":"10.1177\/1740774514552110"},{"key":"S0950268817000747_ref7","first-page":"258","article-title":"Human papillomavirus-associated cancers \u2013 United States, 2004\u20132008","volume":"61","author":"Wu","year":"2012","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"S0950268817000747_ref46","unstructured":"NCT02834637. A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls (MITU-002). In: ClinicalTrials.gov. London School of Hygiene and Tropical Medicine, 2016 (https:\/\/clinicaltrials.gov\/show\/NCT02834637)."},{"key":"S0950268817000747_ref40","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-4199"},{"key":"S0950268817000747_ref61","doi-asserted-by":"publisher","DOI":"10.1086\/597308"},{"key":"S0950268817000747_ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405044"},{"key":"S0950268817000747_ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29959"},{"key":"S0950268817000747_ref37","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000694"},{"key":"S0950268817000747_ref62","unstructured":"Saraiya M . Population-based HPV genotype attribution in HPV-associated cancers. Presented at Anal Intraepithelial Neoplasia Society Conference, March 13\u201315, 2015, Atlanta, GA."},{"key":"S0950268817000747_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.1171"},{"key":"S0950268817000747_ref10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.14639\/0392-100X-621","article-title":"Human papillomavirus-associated cancers: a survey on otorhinolaryngologists\u2019 knowledge and attitudes on prevention","volume":"35","author":"Odone","year":"2015","journal-title":"Acta Otorhinolaryngologica Italica: Organo Ufficiale Della Societa Italiana di Otorinolaringologia e Chirurgia Cervicofacciale"},{"key":"S0950268817000747_ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.06.047"},{"key":"S0950268817000747_ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.1963"},{"key":"S0950268817000747_ref4","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.16.1.1-17.2003"},{"key":"S0950268817000747_ref24","unstructured":"Centers for Disease Control and Prevention. HPV (Human Papillomavirus) VIS (https:\/\/www.cdc.gov\/vaccines\/hcp\/vis\/vis-statements\/hpv.html). Accessed 13 January 2017."},{"key":"S0950268817000747_ref82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106836"},{"key":"S0950268817000747_ref17","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268815002198"},{"key":"S0950268817000747_ref11","first-page":"1","article-title":"Human papillomaviruses","volume":"64","year":"1995","journal-title":"IARC Monographs on the Evaluation of Carcinogenic Risks to Humans \/ World Health Organization, International Agency for Research on Cancer"},{"key":"S0950268817000747_ref54","unstructured":"NCT01254643. A Phase III Open-label, Safety, Tolerability and Immunogenicity Study of a 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 9- to 15-Year-Old Japanese Preadolescent and Adolescent Girls (V503-008). In: ClinicalTrials.gov. Merck Sharp & Dohme Corp., 2010 (http:\/\/clinicaltrials.gov\/show\/NCT01254643)."},{"key":"S0950268817000747_ref38","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1012010"},{"key":"S0950268817000747_ref1","unstructured":"World Health Organization. International Agency for Research on Cancer. Globocan, 2012 (http:\/\/globocan.iarc.fr\/Default.aspx). Accessed 23 August 2016."},{"key":"S0950268817000747_ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23764"},{"key":"S0950268817000747_ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27485"},{"key":"S0950268817000747_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70230-8"},{"key":"S0950268817000747_ref81","unstructured":"EMA. Gardasil 9. European public assessment report. EMA, 2015 (http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003852\/WC500189113.pdf, accessed 22 February 2017)."},{"key":"S0950268817000747_ref45","unstructured":"NCT00543543. A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women (V503\u2013001). In: ClinicalTrials.gov. Merck Sharp & Dohme Corp., 2007 (https:\/\/clinicaltrials.gov\/show\/NCT00543543)."},{"key":"S0950268817000747_ref18","unstructured":"European Medicines Agency. Gardasil. Product information (http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000703\/human_med_000805.jsp). Accessed 3 January 2017."},{"key":"S0950268817000747_ref79","unstructured":"Centers for Disease Control, Prevention (CDC). Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV vaccine, 2015 (https:\/\/www.cdc.gov\/hpv\/downloads\/9vhpv-guidance.pdf, accessed 22 February 2017)."},{"key":"S0950268817000747_ref84","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw046"},{"key":"S0950268817000747_ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.12.063"},{"key":"S0950268817000747_ref26","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2016.1208087"},{"key":"S0950268817000747_ref68","first-page":"425","article-title":"High-risk human papillomavirus genotypes distribution in a cohort of HIV-positive women living in Europe: epidemiological implication for vaccination against human papillomavirus","volume":"30","author":"Konopnicki","year":"2016","journal-title":"AIDS"},{"key":"S0950268817000747_ref60","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-642"},{"key":"S0950268817000747_ref23","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"S0950268817000747_ref57","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1542\/9781581109276-human_papillomaviruses","volume-title":"Red Book: 2015 Report of the Committee on Infectious Diseases","author":"Kimberlin","year":"2015"},{"key":"S0950268817000747_ref48","unstructured":"NCT02568566. A Prospective, Single-Arm, Open-Label, Non-randomized, Phase IIA Trial of a Nonavalent Prophylactic HPV Vaccine to Assess Immunogenicity of a Prime and Deferred-Booster Dosing Schedule Among 9\u201311 Year-Old Girls (NCI-2015-01645). National Cancer Institute (NCI). In: ClinicalTrials.gov, 2015 (https:\/\/clinicaltrials.gov\/show\/NCT02568566)."},{"key":"S0950268817000747_ref5","volume-title":"IARC Monographs on the Evaluation of Carcinogenic Risks to Humans","year":"2007"},{"key":"S0950268817000747_ref52","unstructured":"NCT02653118. A Registry-Based Extension of Protocol V503-001 in Countries With Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, Immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus- Like Particle (VLP) Vaccine as Administered to 16- to 26- Year- Old Women (V503-021). In: ClinicalTrials.gov. Merck Sharp & Dohme Corp., 2016 (https:\/\/clinicaltrials.gov\/show\/NCT02653118)."},{"key":"S0950268817000747_ref8","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6526a1"},{"key":"S0950268817000747_ref12","first-page":"255","article-title":"Human papillomaviruses","volume":"100b","year":"2012","journal-title":"IARC Monographs on the Evaluation of Carcinogenic Risks to Humans\/World Health Organization, International Agency for Research on Cancer"},{"key":"S0950268817000747_ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27608"},{"key":"S0950268817000747_ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25396"},{"key":"S0950268817000747_ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.06.088"},{"key":"S0950268817000747_ref19","unstructured":"European Medicines Agency. Cervarix. Product information (http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000721\/human_med_000694.jsp&mid=WC0b01ac058001d124). Accessed 3 January 2017."},{"key":"S0950268817000747_ref22","unstructured":"European Medicines Agency. Gardasil 9. Product information (http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003852\/human_med_001863.jsp&mid=WC0b01ac058001d124). Accessed 3 January 2017."},{"key":"S0950268817000747_ref27","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw046"},{"key":"S0950268817000747_ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1483-5"},{"key":"S0950268817000747_ref3","unstructured":"The World Health Organization. Human papillomavirus (HPV) and cervical cancer. Fact sheet Updated June 2016 (http:\/\/www.who.int\/mediacentre\/factsheets\/fs380\/en\/). Accessed 4 August 2016."},{"key":"S0950268817000747_ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2015.02.009"},{"key":"S0950268817000747_ref66","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0649"},{"key":"S0950268817000747_ref53","unstructured":"EUCTR2015-005093-38-DE\/AT\/ES\/BE. An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL\u00ae9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16-to-26 Year-Olds) (GDS02C\/V503-004). In: ECTR. Sanofi Pasteur MSD S.N.C, 2016 (https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-005093-38)."},{"key":"S0950268817000747_ref87","first-page":"629","article-title":"[Prevention of HPV cancer related through HPV-9: state of the art, potential benefits and open issues]","volume":"71","author":"Mariani","year":"2015","journal-title":"Igiene e Sanita Pubblica"},{"key":"S0950268817000747_ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.07.015"},{"key":"S0950268817000747_ref85","first-page":"399","article-title":"Update on the new 9-valent vaccine for human papillomavirus prevention","volume":"62","author":"Yang","year":"2016","journal-title":"Canadian Family Physician Medecin de Famille"},{"key":"S0950268817000747_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70137-7"},{"key":"S0950268817000747_ref71","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-7-38"}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268817000747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T23:50:44Z","timestamp":1658965844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268817000747\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,27]]},"references-count":87,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0950268817000747"],"URL":"https:\/\/doi.org\/10.1017\/s0950268817000747","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,27]]},"assertion":[{"value":"Copyright \u00a9 Cambridge University Press 2017\u00a0This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}